Abdominal Candidiasis Is a Hidden Reservoir of Echinocandin Resistance

Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance

Magiorakos, A.-P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03570.x · Cited by 14,449

Clinical and Laboratory Standards Institute

Gressner, A. M., & Arndt, T. (2019) · Springer Reference Medizin · doi:10.1007/978-3-662-48986-4_300416 · Cited by 5,092

Impact of Treatment Strategy on Outcomes in Patients with Candidemia and Other Forms of Invasive Candidiasis: A Patient-Level Quantitative Review of Randomized Trials

Andes, D. R., Safdar, N., Baddley, J. W., Playford, G., Reboli, A. C., Rex, J. H., Sobel, J. D., Pappas, P. G., Kullberg, B. J., & for the Mycoses Study Group (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis021 · Cited by 793

Increasing Echinocandin Resistance in Candida glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations

Alexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778

Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria

Segal, B. H., Herbrecht, R., Stevens, D. A., Ostrosky-Zeichner, L. L., Sobel, J. D., Viscoli, C., Walsh, T. J., Maertens, J. A., Patterson, T. F., Perfect, J. R., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/590566 · Cited by 473

Interlaboratory variability of caspofungin MICs for Candida spp. using CLSI and EUCAST methods: Should the clinical laboratory be testing this agent?

Espinel-Ingroff, A., Arendrup, M. C., Pfaller, M. A., Bonfietti, L. X., Bustamante, B., Canton, E., Chryssanthou, E., Cuenca-Estrella, M., Dannaoui, E., Fothergill, A., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01519-13 · Cited by 216

FKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia

Beyda, N. D., John, J., Kilic, A., Alam, M. J., Lasco, T. M., & Garey, K. W. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu407 · Cited by 174

The Presence of an FKS Mutation Rather than MIC Is an Independent Risk Factor for Failure of Echinocandin Therapy among Patients with Invasive Candidiasis Due to Candida glabrata

Shields, R. K., Nguyen, M. H., Press, E. G., Kwa, A. L., Cheng, S., Du, C., & Clancy, C. J. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00027-12 · Cited by 171

Pharmacodynamics of Caspofungin in a Murine Model of Systemic Candidiasis: Importance of Persistence of Caspofungin in Tissues to Understanding Drug Activity

Louie, A., Deziel, M. R., Liu, W., Drusano, M. F., Gumbo, T., & Drusano, G. L. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.12.5058-5068.2005 · Cited by 164

Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure.

Shields, R. K., Nguyen, M. H., Press, E. G., Updike, C. L., & Clancy, C. J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00136-13 · Cited by 105

Real-world experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates

Eschenauer, G. A., Nguyen, M. H., Shoham, S., Vazquez, J. A., Morris, A. J., Pasculle, W. A., Kubin, C. J., Klinker, K. P., Carver, P. L., Hanson, K. E., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02163-13 · Cited by 61

Candida Peritonitis: An Update on the Latest Research and Treatments

Carneiro, H. A., Mavrakis, A., & Mylonakis, E. E. (2011) · World Journal of Surgery · doi:10.1007/s00268-011-1305-2 · Cited by 56

Anidulafungin and Micafungin MIC Breakpoints Are Superior to That of Caspofungin for Identifying FKS Mutant Candida glabrata Strains and Echinocandin Resistance

Shields, R. K., Nguyen, M. H., Press, E. G., Updike, C. L., & Clancy, C. J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01451-13 · Cited by 56

Disposition of Caspofungin, a Novel Antifungal Agent, in Mice, Rats, Rabbits, and Monkeys

Sandhu, P., Xu, X., Bondiskey, P. J., Balani, S. K., Morris, M. L., Tang, Y. S., Miller, A. R., & Pearson, P. G. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.4.1272-1280.2004 · Cited by 49

Distribution of micafungin in the tissue fluids of patients with invasive fungal infections

Yamada, N., Kumada, K., Ogura, S., Kishino, S., Mochizuki, N., & Ohno, K. (2011) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-011-0240-3 · Cited by 42

Undiagnosed invasive candidiasis: incorporating non-culture diagnostics into rational prophylactic and preemptive antifungal strategies

Clancy, C. J., & Nguyen, M. H. (2014) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2014.919853 · Cited by 39

Candida glabrata Intra-Abdominal Candidiasis Is Characterized by Persistence within the Peritoneal Cavity and Abscesses

Cheng, S., Clancy, C. J., Hartman, D. J., Hao, B., & Nguyen, M. H. (2014) · Infection and Immunity · doi:10.1128/iai.00062-14 · Cited by 39

In Vitro Susceptibility of Breakthrough Candida Bloodstream Isolates Correlates with Daily and Cumulative Doses of Fluconazole

Clancy, C. J., Staley, B. J., & Nguyen, M. H. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00741-06 · Cited by 39

Treatment of Candidal Cholangitis with Caspofungin Therapy in a Patient with a Liver Transplant: Documentation of Biliary Excretion of Caspofungin

Goicoechea, M., Fierer, J., & Johns, S. T. (2004) · Clinical Infectious Diseases · doi:10.1086/382082 · Cited by 20

Invasive candidiasis

Kullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315

The global problem of antifungal resistance: prevalence, mechanisms, and management

Perlin, D. S., Rautemaa-Richardson, R., & Alastruey-Izquierdo, A. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30316-x · Cited by 1,055

Multidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment

Arendrup, M. C., & Patterson, T. F. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix131 · Cited by 707

Candidemia and invasive candidiasis in adults: A narrative review

Antinori, S., Milazzo, L., Sollima, S., Galli, M., & Corbellino, M. (2016) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2016.06.029 · Cited by 259

Defining breakthrough invasive fungal infection–Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology

Cornely, O. A., Hoenigl, M., Lass‐Flörl, C., Chen, S. C. ‐., Kontoyiannis, D. P., Morrissey, C. O., & Thompson, G. R. (2019) · Mycoses · doi:10.1111/myc.12960 · Cited by 229

FKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia

Beyda, N. D., John, J., Kilic, A., Alam, M. J., Lasco, T. M., & Garey, K. W. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu407 · Cited by 174

Emerging echinocandin-resistant Candida albicans and glabrata in Switzerland

Coste, A. T., Kritikos, A., Li, J., Khanna, N., Goldenberger, D., Garzoni, C., Zehnder, C., Boggian, K., Neofytos, D., Riat, A., et al. (2020) · Infection · doi:10.1007/s15010-020-01475-8 · Cited by 69

Increasing Echinocandin Resistance in Candida glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations

Alexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778

Candida glabrata FKS1 and FKS2 Mutations are Linked to Echinocandin Resistance

Perlin, D. S. (2008) · 46th Annual Meeting

Candida albicans and Candida glabrata Clinical Isolates Exhibiting Reduced Echinocandin Susceptibility

Katiyar, S. K., Pfaller, M. A., & Edlind, T. D. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00349-06 · Cited by 189